• Capitalism to strengthen U.S. response capability to epidemics, bioterrorism

    The H1N1 flu pandemic highlighted critical gaps in the response capability of the United States, among them: the United States relies almost entirely on foreign suppliers for influenza vaccines and, perhaps as important, production of vaccines for a novel disease strain can take as long as six months; the U.S. Department of Health and Human Services (HHS) wants to reinvent the U.S. medical countermeasures enterprise, from new doctrines for regulatory approvals to nimble, domestic manufacturing capability developed in partnership with the private sector

  • Increasing cooperation between security, health officials

    Those in charge of preventing and treating man-made diseases (bioterrorism) and those in charge of preventing and treating naturally occurring epidemics have increased cooperation because of a growing recognition by both sides that only way to monitor the rapidly increasing globalization of “dual-use” biological technology — which can be used in regular research efforts or clandestinely put toward a weapons program — is to pool their resources

  • MS drug to lead fight against bioterrorism

    A drug already approved for treating multiple sclerosis show promise as a long sought treatment for victims of bioterrorist attack with botulinum neurotoxin — which is 10,000 times deadlier than cyanide and the most poisonous substance known to man

  • Northrop Grumman testing autonomous biodetection instruments for BioWatch

    DHS has awarded Northrop Grumman a contract to begin field testing a new generation of autonomous biodetection instruments as part of the BioWatch Gen-3 program.; the total potential value of the contract is $37 million over three years

    • view counter

  • U.S. sees East Africa as front line in bioterrorism war

    Africa emerges as the front line in the war against bioterrorism; anthrax killed hundreds of hippopotamuses in Uganda in recent years; in 2008 a Dutch tourist died from Marburg disease after visiting a cave in a national park; in 2007 an Ebola outbreak killed more than twenty people; American officials say that the underlying threat is that lax security at the poorly financed labs that collect and study these and other deadly diseases pose a bioterrorism risk; the rise of Islamist radicals in several countries in East Africa has refocused attention on this region as a frontier in American security interests

  • Detecting use of abnormal organisms as bioterror weapons

    Organisms have the potential to cause disease, but they can be altered to cause an unrecognized diseases or a process a process that doctors have not associated with that organism; this makes altered forms of bacteria like salmonella or E. coli the potential “bombs” in a bio-terrorist attack, but scientists at Purdue University developed a new way to look at those bacteria; now, West Virginia University is testing its potential

    • view counter

  • Concerns over bioterrorism grow

    Recent concern about the growing threat of bioterrorism attacks that could strike cities throughout the world has led governments, militaries, and the biopharmaceutical industry to a heightened state of alert; in response to this threat, the United States is accelerating preparing institutions and procedures for the potential danger

  • U.S. faces growing biological threat

    An international treaty banned biological warfare in 1975, but it had no inspection and verification plan; hundreds of tons of anthrax bacteria and other pathogens were produced by the Soviet Union in violation of the treaty and only ordered destroyed in 1988 as the cold war ended; when U.S. scientists visited the anthrax burial sites, they found live spores had survived

  • SIGA wins $500 million contract to produce smallpox antiviral

    SIGA has received a $500 contract — the contract will be worth as much as $2.8 billion if the government exercises all of its options — to produce the first specialized treatment for smallpox bioterror attacks and related infections; before the company can begin work, it must fend off a legal challenge from Chimerix, Inc., an unsuccessful bidder for the contract; Chimerix claims SIGA misrepresented itself as a small business in order to win this small-business set-aside

  • Synthetic DNA makers alerted to bioterrorism threats

    Scientists have been engineering genetic sequences for decades and commercial gene sequencing has been around for years — but this year, researchers for the first time were able to design and produce cells that do not exist in nature without using pre-existing biological matter — marking the latest evolution in the rapidly advancing field of synthetic biology; the developments could pave the way for advancements in medicine, energy, and agriculture, but also could put sensitive materials in the wrong hands; it will soon be possible to recreate bacterial pathogens like smallpox — and even enhance these pathogens, making them more potent

  • BioWatch system faces technical, operational challenges

    In 2003 U.S. authorities set up a network of air samplers in major cities designed quickly to detect biological agents released in a terrorist attacks; new report says that the system, known as BioWatch, faces “serious technical and operational challenges”

  • DoD awards contract for pathogen detection

    IntegenX wins a $15 million contract to develop a pathogen detection and identification platform; the company will use a technology developed under a previous DoD contract to purify DNA from pathogen targets contained in complex matrices and present the purified material to an IntegenX library construction module

  • Sea floor organisms offer response to bioterrorism

    Two companies, with $30 million funding from the U.S. Defense Threat Reduction Agency, will search for new antibiotics at the bottom of the ocean that could be used to fight bioterrorism; the companies expect to find treatments for the bubonic plague, Yersinia pestis, and other bacterial infections that could be utilized by terror groups for an attack on the United States

  • A new dual vaccine protects against both smallpox and anthrax

    A new protective vaccine against both smallpox and anthrax, two agents of bioterrorism, shows promise in animal models; the new vaccine more quickly elicited immunity and was more effective than the licensed anthrax vaccine, BioThrax, in protecting mice and rabbits against anthrax

  • Georgia county tests drive-thru shot clinic

    Decatur County, Georgia, Health Department’s drive-thru flu shot clinic was held last Friday, and more than 250 people received their vaccination; the important thing, said Sherry Hutchins, Decatur of the County Health Department, is that “The clinic—- gives the health department a chance to test our ability to swiftly, efficiently dispense medicines during a mass-exposure event like a bioterrorism attack, a disaster or an influenza pandemic”